4/23
09:47 am
biib
Biogen (BIIB) had its price target raised by Rothschild & Co Redburn from $150.00 to $180.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Rothschild & Co Redburn from $150.00 to $180.00. They now have a "neutral" rating on the stock.
4/23
09:46 am
biib
Biogen (BIIB) had its price target raised by JPMorgan Chase & Co. from $175.00 to $185.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by JPMorgan Chase & Co. from $175.00 to $185.00. They now have a "neutral" rating on the stock.
4/23
08:42 am
biib
Jim Cramer Says “I Got to Reopen the File on Biogen” [Yahoo! Finance]
Low
Report
Jim Cramer Says “I Got to Reopen the File on Biogen” [Yahoo! Finance]
4/22
08:00 am
biib
Biogen (BIIB) was upgraded by UBS Group AG from "neutral" to "buy". They now have a $225.00 price target on the stock.
Low
Report
Biogen (BIIB) was upgraded by UBS Group AG from "neutral" to "buy". They now have a $225.00 price target on the stock.
4/20
10:47 am
biib
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio [Yahoo! Finance]
Low
Report
Buy 5 Non-Tech Wide Moat Stocks to Strengthen Your Portfolio [Yahoo! Finance]
4/20
07:51 am
biib
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region [Yahoo! Finance]
Medium
Report
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region [Yahoo! Finance]
4/20
07:30 am
biib
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
Low
Report
TJ Biopharma Enters into Agreement with Biogen for Felzartamab Assets in the Greater China Region
4/20
07:30 am
biib
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
Low
Report
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
4/13
09:14 pm
biib
Biogen (BIIB) was upgraded by Piper Sandler from "neutral" to "overweight".
Low
Report
Biogen (BIIB) was upgraded by Piper Sandler from "neutral" to "overweight".
4/13
01:18 pm
biib
Biogen (BIIB) had its price target lowered by Truist Financial Corporation from $193.00 to $189.00. They now have a "hold" rating on the stock.
Low
Report
Biogen (BIIB) had its price target lowered by Truist Financial Corporation from $193.00 to $189.00. They now have a "hold" rating on the stock.
4/13
09:44 am
biib
Biogen (BIIB) had its price target lowered by Citigroup Inc. from $215.00 to $190.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (BIIB) had its price target lowered by Citigroup Inc. from $215.00 to $190.00. They now have a "neutral" rating on the stock.
4/11
05:32 am
biib
Biogen (BIIB) was upgraded by Argus to "hold".
Low
Report
Biogen (BIIB) was upgraded by Argus to "hold".
4/10
10:23 am
biib
Biogen (BIIB) had its price target raised by Morgan Stanley from $190.00 to $200.00. They now have an "equal weight" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Morgan Stanley from $190.00 to $200.00. They now have an "equal weight" rating on the stock.
4/7
09:43 am
biib
Biogen (BIIB) had its price target lowered by Royal Bank Of Canada from $233.00 to $213.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen (BIIB) had its price target lowered by Royal Bank Of Canada from $233.00 to $213.00. They now have an "outperform" rating on the stock.
4/2
08:01 am
biib
Biogen (BIIB) had its price target raised by HC Wainwright from $228.00 to $237.00. They now have a "buy" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by HC Wainwright from $228.00 to $237.00. They now have a "buy" rating on the stock.
4/1
09:09 am
biib
Biogen (BIIB) had its price target raised by Wedbush from $187.00 to $191.00. They now have a "neutral" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Wedbush from $187.00 to $191.00. They now have a "neutral" rating on the stock.
4/1
09:09 am
biib
Biogen (BIIB) had its price target raised by Oppenheimer Holdings, Inc. from $250.00 to $275.00. They now have an "outperform" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Oppenheimer Holdings, Inc. from $250.00 to $275.00. They now have an "outperform" rating on the stock.
4/1
09:09 am
biib
Biogen (BIIB) had its price target raised by Canaccord Genuity Group Inc. from $230.00 to $245.00. They now have a "buy" rating on the stock.
Low
Report
Biogen (BIIB) had its price target raised by Canaccord Genuity Group Inc. from $230.00 to $245.00. They now have a "buy" rating on the stock.
3/31
01:01 pm
biib
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]
Low
Report
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]
3/31
06:59 am
biib
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Low
Report
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
3/30
12:22 pm
biib
Biogen high-dose Spinraza approval seen supporting long-term growth [Yahoo! Finance]
Low
Report
Biogen high-dose Spinraza approval seen supporting long-term growth [Yahoo! Finance]
3/30
07:38 am
biib
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy [Yahoo! Finance]
Low
Report
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy [Yahoo! Finance]
3/30
07:30 am
biib
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Low
Report
FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
3/28
03:19 pm
biib
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity [Yahoo! Finance]
Low
Report
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity [Yahoo! Finance]
3/28
03:00 pm
biib
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
Low
Report
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity